ACEP is proud to bring you the newly revamped Product and Service Showcases. These educational and product-oriented sessions provide you with an in-depth presentation on a product or service you may have seen on the exhibit floor. Show up early—seating is limited to 150 and a boxed meal will be served at each event.

Tuesday

Janssen Pharmaceuticals Product Showcase

Improving Clinical Practice in Patients with AFib
11:30 a.m.–12:15 p.m.
Mandalay Bay Ballroom I
Speaker: Gregory Fermann, MD

This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.

CSL Behring Product Showcase

Treatment Options for Your Patients Requiring Urgent Warfarin Reversal
11:30 a.m.–12:15 p.m.
Mandalay Bay Ballroom K
Speaker: David M. Janicke, MD, PhD

This session focuses on important considerations for the management of patients requiring urgent warfarin reversal. This presentation will use case studies to review key topics for urgent warfarin reversal in patients with acute major bleeding as well as patients requiring urgent surgery.

Fisher & Paykel Healthcare Product Showcase

F&P Optiflow Nasal High Flow Therapy in the Emergency Department—Across the Care Continuum
2:30–3:15 p.m.
Mandalay Bay Ballroom I
Speaker: Gonzalo Hernandez, MD, PhD

In cases of hypoxemic respiratory failure, O2 therapy is one of the principal therapies provided across the care continuum. Traditionally O2 has been delivered using standard nasal prongs or masks. However, patients are unable to tolerate these unconditioned gases limiting the maximal flow rates to 15L/min for standard nasal
prongs or masks. These flow rates are always lower than the inspiratory flow demand for both the hyposemic and many other patients. As a
result, entrained room air dilutes the supplemental oxygen, resulting in
a significant decrease in the fraction of the inspired oxygen (F1O2) finally available at the alveoli. Recently, the efficacious nasal high flow (NHF) therapy, which delivers totally conditioned gas through nasal cannula at a range of flows (up to 60L/min), has emerged. These high flows of gas also provide a degree of positive pressure and a flushing of CO2 from within the nasopharynx. The range of F1O2 that can be accurately delivered is between 21 percent and 100 percent. NHF has many proven clinical and physiological benefits, which are achieved through a variety of mechanisms. The objectives of this showcase are to:

• Identify the current evidence for NHF therapy, including its mechanisms of action.
• Evaluate the emerging and clinically significant applications for NHF therapy.
• Discuss the evidence regarding the use of NHF both in the emergency department and beyond.